Which Therapy Areas Will Dominate Pharma Revenue by 2030

Why this question matters now

Most pharma strategy decks still anchor on 2019, 2023 therapy mix. That’s a problem: the GLP-1 explosion, oncology’s antibody-drug conjugate (ADC) wave, and the IRA’s Medicare price-negotiation list have re-priced entire categories in 18 months. If you’re allocating capital using last year’s revenue distribution, you’re already late.

The right question for 2026 is not “which TAs are big today?”. it’s “which TAs will compound revenue fastest, with defensible margins, by 2030?”

The five therapy areas dominating 2030

1. Oncology. still #1, but with margin pressure

Oncology will remain the largest therapy area by absolute revenue (projected ~$370, 420B globally by 2030, EvaluatePharma consensus). But the dynamics inside oncology are shifting hard:

• ADCs (Enhertu, Trodelvy, datopotamab) are taking share from chemo and from older HER2 antibodies.
• Bispecifics & cell therapy are commanding premium pricing in heme malignancies.
• IRA price negotiation hits the biggest small-molecule oncology drugs first, compressing late-cycle revenue.

Decision implication: Don’t just bet on “oncology”. bet on the modality slice. ADC and bispecific assets command the highest deal multiples right now.

2. Obesity & cardiometabolic (GLP-1 and beyond)

Semaglutide and tirzepatide redefined what a single therapy area can be worth. The GLP-1 class alone is projected at $130, 200B by 2030. The next wave. oral GLP-1, GLP-1/GIP/glucagon triagonists, amylin combos. will expand both the addressable market and the margin pool.

Decision implication: Anyone without a metabolic franchise is paying premium multiples to buy in. Anyone with one is being pursued.

3. Immunology

Humira’s loss of exclusivity reset the category, but immunology is far from over. IL-17, IL-23, JAK-class and oral selective T-cell agents will redistribute the $150B+ category. Atopic dermatitis, IBD and psoriatic arthritis are still under-treated globally.

4. Rare & genetic disease

Per-patient pricing of $300K-$3M+ makes rare disease the highest-margin growth segment. Gene therapies (Casgevy, Hemgenix, Zolgensma) prove the willingness-to-pay. The CMS rare-disease payment models being piloted in 2026 will determine ceiling.

5. Neurology (Alzheimer’s, depression, MS)

Anti-amyloid antibodies (Leqembi, donanemab) opened a market everyone wrote off. KarXT and rapid-acting antidepressants are reframing schizophrenia and MDD. Neuroscience moved from “abandoned” to “next frontier” in 36 months.

Therapy area revenue forecast (2030, projected)

Sources: EvaluatePharma 2024, IQVIA Institute, GlobalData. Figures rounded; consensus midpoint shown.

The framework: how to read these numbers for capital allocation

Absolute size is misleading. What matters is incremental revenue × margin × strategic optionality. By that lens:

1. Best risk-adjusted growth: Obesity/cardiometabolic. large incremental pool, premium margins, oral pipeline emerging.
2. Best margin density: Rare disease. small patient counts, very high price points, durable IP.
3. Best modality optionality: Oncology ADCs & bispecifics. platform plays usable across multiple tumor types.
4. Best contrarian bet: Neurology. was abandoned, now compounding.

What this means for your portfolio decision

If you are in pharma strategy, BD or as a healthcare investor, the action item is concrete:

• Re-score your portfolio against the 2030 revenue mix, not the 2023 mix.
• Stress-test every late-stage asset against IRA negotiation exposure.
• Quantify your “modality concentration”. are you over-indexed on small molecules in TAs where biologics dominate?
• Identify the white-space TA where your platform technology has structural advantage.

The teams that win the 2025, 2027 capital cycle won’t be the ones with the biggest TA presence today. They’ll be the ones who re-allocated before the consensus did.

Frequently Asked Questions

Which therapy area will be the biggest by 2030?

Oncology will remain the largest therapy area by absolute revenue (~$390B projected), but obesity / cardiometabolic (GLP-1 class) will be the fastest-growing, expanding from ~$45B to ~$165B at a 24% CAGR.

Will the IRA Medicare price negotiation change therapy-area dynamics?

Yes, materially. The first negotiation lists target high-revenue small-molecule oncology and cardiometabolic drugs, which compresses late-lifecycle revenue. Biologics, vaccines and orphan drugs are temporarily protected, accelerating capital flow into those categories.

Is rare disease really a growth area despite small patient populations?

Yes. Per-patient pricing of $300K-$3M and very high margins make rare/genetic disease the highest-margin growth segment in pharma. Gene therapies have proven willingness-to-pay; CMS rare-disease pilots in 2026 will set durability.

How should pharma teams use this data for portfolio decisions?

Re-score every asset against the 2030 revenue mix (not 2023), stress-test for IRA exposure, quantify modality concentration risk, and identify white-space TAs where your platform has structural advantage.

References & Further Reading

• EvaluatePharma — World Preview 2030
• IQVIA Institute — Global Use of Medicines
• CMS — Medicare Drug Price Negotiation
• FDA — Drug Approvals & Databases

Related decisions to read next

• Oncology vs Cardiology: Where Capital Is Shifting (Data-Backed)
• Fastest Growing Pharma Markets by Geography (US, EU, APAC)
• Biotech Modalities Explained: Which Platform Will Win (mRNA vs Gene vs Cell)

Take the next decision

This brief is part of the Pharma & Biotech Decision Intelligence hub at Widelly. It is built for strategy, BD and investor teams who need to convert live healthcare data into defensible decisions.